HOME › DRUGS › PEGCETACOPLAN
ACTIVE SUBSTANCE / INN

PEGCETACOPLAN

Brand name(s): Syfovre, EMPAVELI, SYFOVRE, Aspaveli
FDA LISTED
EMA LISTED
PRESCRIPTION
REFUSED
AUTHORISED
NDA215014
Hemoglobinuria, Paroxysmal
ACTIVE SUBSTANCE
Pegcetacoplan
REGULATORS
FDA · EMA
SPONSORS / MAH
Swedish Orphan Biovitrum AB (publ), Apellis Europe B.V., APELLIS PHARMS
TOTAL APPLICATIONS
4
FDA APPLICATIONS (DRUGS@FDA)
BRAND NAMEAPPLICATIONSPONSORSTATUS
SYFOVRENDA217171APELLIS PHARMSPrescription
EMPAVELINDA215014APELLIS PHARMSPrescription
EMA AUTHORISATIONS
PRODUCT NAMEHOLDERSTATUSDATEINDICATION
AspaveliSwedish Orphan Biovitrum AB (publ)Authorised13/12/2021Hemoglobinuria, Paroxysmal
SyfovreApellis Europe B.V.RefusedMacular Degeneration;Geographic Atrophy

FULL INTELLIGENCE ON PEGCETACOPLAN

Patent cliffs, clinical trials, pipeline data, AI-enriched regulatory signals — free on PharmaSignal.

OPEN PLATFORM →